

FRAGMENT-BASED


CAPABILITIES OVERVIEW

• Screening


- » Ligand observe NMR methods: STD, wLOGSY, CPMG
- Library Preparation
 - » Identity, solubility, purity
 - » Automated smart pooling
- Follow-up Analysis
 - » Validation (follow-up singletons)
 - » Rank-order; cluster
- Target Generation
 - » Protein generation and purification
- Target Preparation
 - » Screen design; sample optimization; experimental conditions optimization
- Complimentary Capabilities
 - » Orthogonal methods (SPR)
 - » X-Ray Crystallography
 - » Computational Chemistry
 - » Chemical elaboration to support optimization
 - » Biological assay design and support

LIBRARY SCREENING OPTIONS


- Fragment Library
- Commercial and Proprietary
 - » Fragment sets from internal small molecule collections
 - » Fragment sets designed from FDA approved drugs
 - » ¹⁹F- containing fragments
 - » Covalent fragments
 - » Commercial fragments
- External libraries
 - » Client-provided
 - » Client-selected commercial libraries
 - » Custom commercial libraries



SELECT FRAGMENT LIBRARY PROPERTIES




CUTTING EDGE SCREENING PLATFORM



CASE STUDY: FRAGMENT-BASED DRUG DESIGN OF NOVEL NAMPT SCAFFOLDS

NAMPT (nicotinamide phosphoribosyltransferase): An oncology target in the cellular metabolism pathway.

Primary Screening: STD NMR of 1000 fragments in 100 pools. Hits were selected based on structural diversity, virtual screening and the strength of the STD signals from the primary screen



ChemPartner www.ChemPartner.com 280 Utah Ave South San Francisco, CA 94080-6812 650-746-4884 | contact@chempartner.com